RD 792.34234

RD 792.34234 is an investigational small molecule P2X7 receptor antagonist developed by Cardiff University's Medicines Discovery Institute. The P2X7 receptor is an ATP-gated ion channel primarily expressed on immune cells, including microglia in the central nervous system, where it plays a key role in the NLRP3 inflammasome pathway and the subsequent release of pro-inflammatory cytokines such as interleukin-1β (IL-1β). By inhibiting P2X7, RD 792.34234 is designed to modulate neuroinflammation, a process implicated in the pathophysiology of various neuropsychiatric and neurodegenerative conditions, including treatment-resistant depression and Alzheimer's disease. The compound entered Phase I first-in-human clinical trials in 2022 to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers, with specific trial details deferred under UK Health Research Authority (HRA) approval protocols.